Literature DB >> 18951974

Altered EGFR localization and degradation in human breast cancer cells with an amphiregulin/EGFR autocrine loop.

Nicole E Willmarth1, Andrea Baillo, Michele L Dziubinski, Kristy Wilson, David J Riese, Stephen P Ethier.   

Abstract

The epidermal growth factor receptor (EGFR) and its ligand amphiregulin (AR) have been shown to be co-over expressed in breast cancer. We have previously shown that an AR/EGFR autocrine loop is required for SUM149 human breast cancer cell proliferation, motility and invasion. We also demonstrated that AR can induce these altered phenotypes when expressed in the normal mammary epithelial cell line MCF10A, or by exposure of these cells to AR in the medium. In the present studies, we demonstrate that SUM149 cells and immortalized human mammary epithelial MCF10A cells that over express AR (MCF10A AR) or are cultured in the presence of exogenous AR, express higher levels of EGFR protein than MCF10A cells cultured in EGF. Pulse-chase analysis showed that EGFR protein remained stable in the presence of AR, yet was degraded in the presence of EGF. Consistent with this observation, tyrosine 1045 on the EGFR, the c-cbl binding site, exhibited less phosphorylation following stimulation with AR than following stimulation with EGF. Ubiquitination of the receptor was also dramatically less following stimulation with AR than following stimulation with EGF. Flow cytometry analysis showed that EGFR remained on the cell surface following stimulation with AR but was rapidly internalized following stimulation with EGF. Immunofluorescence and confocal microscopy confirmed the flow cytometry results. EGFR in MCF10A cells cultured in the presence of EGF exhibited a predominantly intracellular, punctate localization. In stark contrast, SUM149 cells and MCF10A cells growing in the presence of AR expressed EGFR predominantly on the membrane and at cell-cell junctions. We propose that AR alters EGFR internalization and degradation in a way that favors accumulation of EGFR at the cell surface and ultimately leads to changes in EGFR signaling.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18951974      PMCID: PMC2632975          DOI: 10.1016/j.cellsig.2008.10.003

Source DB:  PubMed          Journal:  Cell Signal        ISSN: 0898-6568            Impact factor:   4.315


  45 in total

1.  Isolation of a mouse submaxillary gland protein accelerating incisor eruption and eyelid opening in the new-born animal.

Authors:  S COHEN
Journal:  J Biol Chem       Date:  1962-05       Impact factor: 5.157

Review 2.  Epidermal growth factor receptor (EGFR) signaling in cancer.

Authors:  Nicola Normanno; Antonella De Luca; Caterina Bianco; Luigi Strizzi; Mario Mancino; Monica R Maiello; Adele Carotenuto; Gianfranco De Feo; Francesco Caponigro; David S Salomon
Journal:  Gene       Date:  2005-12-27       Impact factor: 3.688

3.  The evolutionarily conserved N-terminal region of Cbl is sufficient to enhance down-regulation of the epidermal growth factor receptor.

Authors:  N L Lill; P Douillard; R A Awwad; S Ota; M L Lupher; S Miyake; N Meissner-Lula; V W Hsu; H Band
Journal:  J Biol Chem       Date:  2000-01-07       Impact factor: 5.157

4.  Regulation of epidermal growth factor receptor signaling by endocytosis and intracellular trafficking.

Authors:  P Burke; K Schooler; H S Wiley
Journal:  Mol Biol Cell       Date:  2001-06       Impact factor: 4.138

5.  A functional screen for genes inducing epidermal growth factor autonomy of human mammary epithelial cells confirms the role of amphiregulin.

Authors:  I M Berquin; M L Dziubinski; G P Nolan; S P Ethier
Journal:  Oncogene       Date:  2001-07-05       Impact factor: 9.867

6.  Development of mammary hyperplasia and neoplasia in MMTV-TGF alpha transgenic mice.

Authors:  Y Matsui; S A Halter; J T Holt; B L Hogan; R J Coffey
Journal:  Cell       Date:  1990-06-15       Impact factor: 41.582

7.  Epiregulin. A novel epidermal growth factor with mitogenic activity for rat primary hepatocytes.

Authors:  H Toyoda; T Komurasaki; D Uchida; Y Takayama; T Isobe; T Okuyama; K Hanada
Journal:  J Biol Chem       Date:  1995-03-31       Impact factor: 5.157

8.  A heparin-binding growth factor secreted by macrophage-like cells that is related to EGF.

Authors:  S Higashiyama; J A Abraham; J Miller; J C Fiddes; M Klagsbrun
Journal:  Science       Date:  1991-02-22       Impact factor: 47.728

9.  Autophosphorylation sites on the epidermal growth factor receptor.

Authors:  J Downward; P Parker; M D Waterfield
Journal:  Nature       Date:  1984 Oct 4-10       Impact factor: 49.962

10.  Ligand-induced lysosomal epidermal growth factor receptor (EGFR) degradation is preceded by proteasome-dependent EGFR de-ubiquitination.

Authors:  Husam A J Alwan; Everardus J J van Zoelen; Jeroen E M van Leeuwen
Journal:  J Biol Chem       Date:  2003-06-26       Impact factor: 5.157

View more
  29 in total

Review 1.  EGFR ligands exhibit functional differences in models of paracrine and autocrine signaling.

Authors:  Kristy J Wilson; Christopher Mill; Sydney Lambert; Jennifer Buchman; Timothy R Wilson; Victor Hernandez-Gordillo; Richard M Gallo; Laura M C Ades; Jeffrey Settleman; David J Riese
Journal:  Growth Factors       Date:  2012-01-20       Impact factor: 2.511

2.  Small molecule inhibitors of the host cell COX/AREG/EGFR/ERK pathway attenuate cytomegalovirus-induced pathogenesis.

Authors:  Michael Melnick; George Abichaker; Khine Htet; Parish Sedghizadeh; Tina Jaskoll
Journal:  Exp Mol Pathol       Date:  2011-05-01       Impact factor: 3.362

Review 3.  EGFR signaling in breast cancer: bad to the bone.

Authors:  John Foley; Nicole K Nickerson; Seungyoon Nam; Kah Tan Allen; Jennifer L Gilmore; Kenneth P Nephew; David J Riese
Journal:  Semin Cell Dev Biol       Date:  2010-09-09       Impact factor: 7.727

4.  RIN1 orchestrates the activation of RAB5 GTPases and ABL tyrosine kinases to determine the fate of EGFR.

Authors:  Kavitha Balaji; Chelsea Mooser; Christine M Janson; Joanne M Bliss; Houmehr Hojjat; John Colicelli
Journal:  J Cell Sci       Date:  2012-09-12       Impact factor: 5.285

5.  Sustained activation of the HER1-ERK1/2-RSK signaling pathway controls myoepithelial cell fate in human mammary tissue.

Authors:  Lejla Pasic; T S Karin Eisinger-Mathason; Bisi T Velayudhan; Christopher A Moskaluk; David R Brenin; Ian G Macara; Deborah A Lannigan
Journal:  Genes Dev       Date:  2011-08-01       Impact factor: 11.361

Review 6.  At the crossroads: EGFR and PTHrP signaling in cancer-mediated diseases of bone.

Authors:  John Foley; Nicole Nickerson; David J Riese; Peter C Hollenhorst; Gwendolen Lorch; Anne M Foley
Journal:  Odontology       Date:  2012-06-10       Impact factor: 2.634

7.  Ligand-based receptor tyrosine kinase partial agonists: New paradigm for cancer drug discovery?

Authors:  David J Riese
Journal:  Expert Opin Drug Discov       Date:  2011-02       Impact factor: 6.098

8.  Membranous and cytoplasmic expression of epidermal growth factor receptor in metastatic pancreatic ductal adenocarcinoma.

Authors:  Takahiro Einama; Shigeto Ueda; Hitoshi Tsuda; Kazuhiro Ogasawara; Kazuo Hatsuse; Osamu Matsubara; Satoru Todo; Junji Yamamoto
Journal:  Exp Ther Med       Date:  2012-03-15       Impact factor: 2.447

9.  Autocrine-derived epidermal growth factor receptor ligands contribute to recruitment of tumor-associated macrophage and growth of basal breast cancer cells in vivo.

Authors:  Nicole K Nickerson; Christopher P Mill; Hsin-Jung Wu; David J Riese; John Foley
Journal:  Oncol Res       Date:  2013       Impact factor: 5.574

10.  Reconstitution of amphiregulin-epidermal growth factor receptor signaling in lung squamous cell carcinomas activates PTHrP gene expression and contributes to cancer-mediated diseases of the bone.

Authors:  Jennifer L Gilmore; Ryan M Gonterman; Keshav Menon; Gwendolen Lorch; David J Riese; Alex Robling; John Foley
Journal:  Mol Cancer Res       Date:  2009-10-13       Impact factor: 5.852

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.